Cinaciguat
| Title | Journal |
|---|---|
| Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. | Handbook of experimental pharmacology 20170101 |
| Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment. | Journal of clinical pharmacology 20121101 |
| Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. | European journal of heart failure 20120901 |
| Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose. | Journal of clinical pharmacology 20120801 |
| Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat. | Chembiochem : a European journal of chemical biology 20120507 |
| Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. | American journal of physiology. Heart and circulatory physiology 20120315 |
| Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain. | The Journal of pharmacology and experimental therapeutics 20120301 |
| Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. | Critical care research and practice 20120101 |
| Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. | American journal of physiology. Lung cellular and molecular physiology 20111101 |
| NOX1, 2, 4, 5: counting out oxidative stress. | British journal of pharmacology 20111001 |
| Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. | Atherosclerosis 20111001 |
| New perspectives for the treatment of pulmonary hypertension. | British journal of pharmacology 20110501 |
| Soluble guanylate cyclase modulators in heart failure. | Current heart failure reports 20110301 |
| Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. | European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20110201 |
| Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure. | Cardiology in review 20110101 |
| Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. | PloS one 20110101 |
| The amino-terminus of nitric oxide sensitive guanylyl cyclase α₁ does not affect dimerization but influences subcellular localization. | PloS one 20110101 |
| Identification of residues in the heme domain of soluble guanylyl cyclase that are important for basal and stimulated catalytic activity. | PloS one 20110101 |
| Direct fusion of subunits of heterodimeric nitric oxide sensitive guanylyl cyclase leads to functional enzymes with preserved biochemical properties: evidence for isoform specific activation by ciguates. | Biochemical pharmacology 20101201 |
| Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. | Current opinion in investigational drugs (London, England : 2000) 20100901 |
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. | The Journal of biological chemistry 20100716 |
| Nitric oxide sensitive guanylyl cyclase activity decreases during cerebral postnatal development because of a reduction in heterodimerization. | Journal of neurochemistry 20100101 |
| Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure. | Clinical pharmacokinetics 20100101 |
| Animal models related to congenital heart disease and clinical research in pulmonary hypertension. | Cardiology 20100101 |
| Fluorescent fusion proteins of soluble guanylyl cyclase indicate proximity of the heme nitric oxide domain and catalytic domain. | PloS one 20100101 |
| Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase. | Vascular pharmacology 20100101 |
| Vasodilators in the treatment of acute heart failure: what we know, what we don't. | Heart failure reviews 20091201 |
| Role of guanylate cyclase modulators in decompensated heart failure. | Heart failure reviews 20091201 |
| Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor. | Arteriosclerosis, thrombosis, and vascular biology 20091001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091001 |
| Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. | Circulation 20090825 |
| Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. | American journal of physiology. Lung cellular and molecular physiology 20090801 |
| Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel. | Investigative ophthalmology & visual science 20090701 |
| BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. | European heart journal 20090701 |
| Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. | British journal of pharmacology 20090701 |
| Soluble guanylate cyclase: not a dull enzyme. | Circulation 20090602 |
| Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. | Circulation 20090602 |
| NO- and haem-independent soluble guanylate cyclase activators. | Handbook of experimental pharmacology 20090101 |
| Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. | Journal of clinical pharmacology 20081201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080501 |
| Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. | British journal of pharmacology 20080401 |
| Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. | American journal of respiratory and critical care medicine 20071201 |
| Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. | European journal of pharmacology 20071015 |
| Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? | Hypertension (Dallas, Tex. : 1979) 20070501 |
| Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. | Hypertension (Dallas, Tex. : 1979) 20070501 |
| Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. | Cardiovascular drug reviews 20070101 |
| Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. | The Journal of clinical investigation 20060901 |
| Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. | The Journal of clinical investigation 20060901 |
| NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. | British journal of pharmacology 20060701 |
| Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. | Circulation 20060117 |
| Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. | Molecular pharmacology 20051201 |
| Clinical potential of nitric oxide-independent soluble guanylate cyclase activators. | Current opinion in investigational drugs (London, England : 2000) 20050901 |
| Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. | European journal of pharmacology 20050418 |
| A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. | Analytical biochemistry 20050401 |
| Preparation of heme-free soluble guanylate cyclase. | Protein expression and purification 20030901 |
| Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. | European journal of pharmacology 20030516 |
| NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. | British journal of pharmacology 20020701 |